#75
Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
Clinicians should be aware that emerging evidence does not support cannabis as an effective treatment for anxiety or depression, which contradicts patient expectations and direct-to-consumer marketing claims. Patients seeking cannabis for mood or anxiety symptoms need evidence-based counseling about lack of efficacy data and should be directed toward established treatments like SSRIs or psychotherapy instead. This evidence gap is critical as clinicians may increasingly encounter patients requesting cannabis for psychiatric conditions where standard-of-care alternatives remain more effective.
A recent study challenges the widespread clinical assumption that medicinal cannabis effectively treats anxiety and depression, two of the most common reasons patients seek cannabis treatment. The research suggests that evidence supporting cannabis use for these psychiatric conditions remains limited, and current clinical practice may not align with the strength of available data. This finding is particularly important given that anxiety and depression represent substantial portions of cannabis prescriptions in many jurisdictions, raising questions about whether clinicians are adequately counseling patients on efficacy uncertainty. Additionally, the study highlights potential neurobiological concerns, with separate research linking cannabis use in middle-aged and older adults to structural brain changes, which could have implications for long-term safety in these populations. Clinicians should reconsider their counseling approach regarding cannabis for mood and anxiety disorders, emphasizing that evidence-based first-line treatments such as selective serotonin reuptake inhibitors and psychotherapy remain more rigorously supported. Patients seeking cannabis for anxiety or depression should be informed of the limited clinical evidence, offered established alternatives, and monitored closely if they choose to proceed with cannabis use.
“What we’re seeing in the literature is that cannabinoid products are far less effective for anxiety and depression than patients hope they’ll be, and in some cases they actually worsen these conditions, particularly when THC dominance is involved. I tell my patients that if cannabis is their primary strategy for mood or anxiety, we need a much more honest conversation about the evidence and typically need to pursue first-line treatments like therapy or SSRIs instead.”
? While cannabis is increasingly sought by patients for anxiety and depression, emerging evidence suggests limited efficacy for these common mental health conditions, warranting careful patient counseling. This finding contrasts with patient expectations and online promotion, yet reflects the modest evidence base for cannabinoids in mood and anxiety disorders compared to established psychopharmacology. Importantly, cannabis use carries potential risks including cognitive effects, dependency, and drug interactions that must be weighed against unproven benefits, particularly in patients already on psychiatric medications. The heterogeneity of cannabis products, dosing regimens, and cannabinoid profiles complicates evidence synthesis and makes it difficult to draw definitive conclusions about specific formulations. Clinicians should discuss realistic expectations with patients seeking cannabis for anxiety or depression, emphasize evidence-based treatments like SSRIs or psychotherapy as first-line options, and document their rationale if cannabis is considered, while remaining alert to emerging safety data in this rapidly
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
Have thoughts on this? Share it:
Read next
